TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report report published on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $10.00 target price on the stock.

TLSI has been the subject of a number of other research reports. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 target price for the company. Oppenheimer began coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Canaccord Genuity Group lowered their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Stock Down 4.3 %

NASDAQ TLSI opened at $3.60 on Tuesday. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42. The firm has a 50 day moving average of $4.14 and a two-hundred day moving average of $4.96. The stock has a market capitalization of $109.77 million, a PE ratio of -1.45 and a beta of 0.56.

Insider Buying and Selling

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius purchased 62,972 shares of TriSalus Life Sciences stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the transaction, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have bought 70,012 shares of company stock worth $281,235 in the last quarter. 32.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares during the period. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at approximately $1,184,000. Geode Capital Management LLC lifted its position in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the period. Wolverine Asset Management LLC purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Finally, MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $184,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.